Andere Kunden interessierten sich auch für
![Cérebro - do desenvolvimento à neoplasia, e solução de terapia genética]( "Cérebro - do desenvolvimento à neoplasia, e solução de terapia genética")
Cérebro - do desenvolvimento à neoplasia, e solução de terapia genética42,99 €![Cervello: dallo sviluppo alla neoplasia e soluzione per la terapia genica]( "Cervello: dallo sviluppo alla neoplasia e soluzione per la terapia genica")
Cervello: dallo sviluppo alla neoplasia e soluzione per la terapia genica42,99 €![Le cerveau - du développement à la néoplasie, et la solution de la thérapie génique]( "Le cerveau - du développement à la néoplasie, et la solution de la thérapie génique")
Le cerveau - du développement à la néoplasie, et la solution de la thérapie génique42,99 €![Das Gehirn - von der Entwicklung bis zur Neoplasie und die Gentherapie als Lösung]( "Das Gehirn - von der Entwicklung bis zur Neoplasie und die Gentherapie als Lösung")
Das Gehirn - von der Entwicklung bis zur Neoplasie und die Gentherapie als Lösung64,90 €![Metastasis To and From the Jaws]( "Metastasis To and From the Jaws")
Metastasis To and From the Jaws27,99 €![Adenoviral Vectors for Gene Therapy]( "Adenoviral Vectors for Gene Therapy")
Adenoviral Vectors for Gene Therapy133,99 €![Meta-analysis on Revolutionizing Sickle Cell Disease Management]( "Meta-analysis on Revolutionizing Sickle Cell Disease Management")
Meta-analysis on Revolutionizing Sickle Cell Disease Management29,99 €
Differentiation of nervous tissue, which occurs during CNS development, was first described in detail while investigating a model of rat brain through the use of a new biomarker known as alpha-fetoprotein, AFP. During this research, another model -mouse teratocarcinoma - enabled the description of the different steps of nervous tissue formation following distinct pathological ways of CNS development. Comparing these two processes gave rise to the following conclusions: a striking convergence exists between normal and neoplastic nervous tissue development and correlates with the presence of oncoproteins such as AFP and growth factor IGF-I. These interesting observations have oriented the pursuit of one goal: stopping the neoplastic CNS development conducing to the malignant tumor - glioblastoma. From this endeavor, stemmed an efficient anti-gene strategy targeting gene of growth factor IGF-I present in brain tumor development, inducing immune anti-tumor response and consequently, increasing the median survival of glioblastoma patients up to 2 years.